Introduction
============

Syndecan-1/CD138 (Sdc1) is a cell surface heparan sulphate proteoglycan that is highly expressed by epithelial and plasma cells. Via its heparan sulphate chains, Sdc1 binds to a variety of growth and angiogenic factors and acts as a classical coreceptor for growth factor receptors, thus promoting cell proliferation \[[@B1]\]. Moreover, Sdc1 interacts with ligands in the extracellular matrix and on cell surfaces, functioning as a cell adhesion molecule \[[@B1]\]. We recently showed that Sdc1 is a modulator of proteolytic activities and chemokine functions *in vivo*, which orchestrates leucocyte recruitment and tissue remodelling during inflammation and wound repair \[[@B2]-[@B4]\]. In Sdc1-deficient and Sdc1-overexpressing mouse models, abnormal blood vessel formation is observed during wound repair, confirming a role for Sdc1 as a regulator of angiogenesis *in vivo*\[[@B2],[@B4]\]. Because the biological functions of Sdc1 potentially affect several steps in tumour progression, it is not surprising that a prognostic value has been assigned to changes in Sdc1 expression in several cancer types, including colorectal, gastric, pancreatic, prostate, lung, endometrial and ovarian cancers, as well as squamous cell carcinoma of the head and neck (for review, see Yip and coworkers \[[@B5]\]). In breast cancer, increased expression of Sdc1 correlates with an unfavourable prognosis \[[@B6]-[@B8]\] and poor response to chemotherapy \[[@B9]\]. Of note, several proteins that are functionally linked to Sdc1 by virtue of their biology are prognostic markers on their own (Table [1](#T1){ref-type="table"}). In multiple myeloma, Sdc1 mediates ligand binding and signalling through the hepatocyte growth factor (HGF) receptor tyrosine kinase c-met, resulting in increased cancer cell proliferation \[[@B10]\].

Similar mechanisms may be of relevance in breast cancer, because prognostic value has been established for c-met expression in a number of clinical studies of breast cancer patients (Table [1](#T1){ref-type="table"}). Signal transduction mediated by c-met modulates cell dissociation and motility, and protease overexpression \[[@B11],[@B12]\]. Moreover, ribozyme targeting of c-met in mammary cancer cells reduced mammary cancer and tumour-associated angiogenesis in a xenograft model \[[@B12]\]. To mobilize its full transforming potential in breast cancer, c-met appears to depend on coactivating factors, such as overexpression of additional proto-oncogenes (MYC, RON), or β~4~integrin activity \[[@B13]-[@B15]\]. Similarly, Sdc1 regulates α~v~β~3~integrin activation and signalling in breast cancer cell lines \[[@B16],[@B17]\]. Sdc1-integrin complexes may thus synergistically contribute to tumour progression driven by c-met overexpression.

The calcium-dependent cell-cell adhesion molecule E-cadherin (E-cad) is an established prognostic marker in breast cancer (Table [1](#T1){ref-type="table"}). E-cad expression is irreversibly lost in invasive lobular breast cancer, and this feature has been used by pathologists to distinguish between ductal and lobular neoplasia \[[@B18]-[@B20]\]. Like Sdc1, E-cad is mostly present in epithelial cells, and is required for maintaining the epitheloid phenotype and inhibition of density-dependent cell growth \[[@B21]\]. Coordinated regulation of E-cad and Sdc1 expression is seen during development \[[@B22]\] and in mammary tumour cells subjected to antisense RNA mediated downregulation of Sdc1 \[[@B23]\] or E-cad \[[@B24]\], respectively. Sdc1 and E-cad colocalize and coimmunoprecipitate with the transcriptional regulator β-catenin in epithelial cells, suggesting both a functional and physical association \[[@B25]\]. Of note, expression of Sdc1 is required for proper development of a β-catenin responsive mammary epithelial progenitor cell population, which appears to be the mechanistic principle underlying resistance of Sdc1-deficient mice to wnt-1 mediated breast cancer \[[@B5],[@B26]-[@B28]\].

In the present study we evaluated coexpression of the three functionally linked prognostic factors, namely Sdc1, E-cad and c-met, in ductal carcinoma *in situ*(DCIS) of the breast by semiquantitative immunohistochemistry of a tissue microarray containing tumour specimens from 200 patients. We recently showed that several proangiogenic factors, including fibroblast growth factor receptor (FGFR)-1, vascular endothelial growth factor (VEGF)-C, its receptor Flt-4, and the endothelin A receptor (ET~A~R), are highly expressed in DCIS, suggesting that *in situ*carcinomas can induce angiogenesis and lymphangiogenesis \[[@B29]\]. Although expression of endothelin and VEGF receptors was previously believed to be largely restricted to the vascular endothelium, these receptors have also been detected in breast cancer cells, suggesting an autocrine effect of their ligands on tumour cells \[[@B29]-[@B31]\]. Because Sdc1 and c-met modulate angiogenesis *in vivo*\[[@B2],[@B4],[@B12],[@B32],[@B33]\], we determined the association of these molecules with markers of angiogenesis and lymphangiogenesis in DCIS. Moreover, we characterized the coexpression of Sdc1, E-cad and c-met in three differently aggressive human breast cancer cell lines by RT-PCR and by confocal immunofluorescence microscopy. The aim of the study was to determine whether coexpression of the functionally linked molecular markers Sdc1, E-cad and c-met may constitute a novel angiogenesis-associated molecular marker signature in DCIS.

Materials and methods
=====================

Cell culture and confocal immunofluorescence microscopy
-------------------------------------------------------

The human breast cancer cell lines MCF-7 and MDA-MB468 were from our cell culture collection \[[@B34]\]. MCF-7 cells were cultured in RPMI-1640 medium (Gibco, Karlsruhe, Germany) supplemented with 10% foetal calf serum (PAA, Cölbe, Germany) and 2 mmol/l L-glutamine. MDA-MB231 (CLS Cell Lines Service, Eppelheim, Germany) and MDA-MB468 cells were maintained in DMEM (Dulbecco\'s modified Eagle medium) high-glucose medium (Invitrogen, Karlsruhe, Germany) supplemented with 1% L-glutamine, 1% penicillin-streptomycin and 10% foetal calf serum at 7.5% carbon dioxide. For immunocytochemistry, cells were grown to 80% confluence in eight-well chamber slides (Corning Costar, Wiesbaden, Germany), fixed with ice-cold methanol, and subjected to immunostaining as follows. After a 30 min blocking step with phosphate-buffered saline (PBS) containing 10% goat serum (DAKO, Glostrup Denmark), the slides were washed with PBS, and the following primary antibodies were used in an overnight incubation at 4°C at a dilution of 1:100 in PBS/1% bovine serum albumin: mouse anti-syndecan-1 (clone BB4; Serotec, Duesseldorf, Germany), rabbit anti-c-met (Santa Cruz, Santa Cruz, CA, USA), and mouse anti-E-cadherin (BD Transduction Laboratories, San Diego, CA, USA). The slides were washed three times for 5 min with PBS and incubated with AlexaFluor 546-conjugated goat-anti-mouse IgG (Invitrogen) and AlexaFluor 488 conjugated donkey-anti-rabbit IgG (Invitrogen) secondary antibodies in PBS/1% bovine serum albumin at a dilution of 1:600 at room temperature for 30 min. Samples that were incubated without a primary antibody served as controls. Slides were washed three times for 5 min with PBS and mounted using VectaShield (Vector Labs, Burlingame, CA, USA). Laser scanning microscopy was performed using a Leica TCS SL confocal microscope (Leica, Bensheim, Germany).

RT-PCR analysis
---------------

For RT-PCR analysis, total cellular RNA was prepared from MCF-7, MDA-MB468, and MDA-MB231 cells using the RNeasy Mini kit (Qiagen, Hilden, Germany) in the presence of RNAse-free DNAse. Total RNA 1 μg was reverse transcribed using the Advantage RT-for-PCR Kit (BD Clontech, Heidelberg, Germany) and amplified in a BioMetra PCR reactor (BioMetra, Göttingen, Germany). A DNA fragment corresponding to base pairs 1233--1303 of human Sdc-1 mRNA (accession \# NM_001006946.1) was amplified using the primers 5\'-AGGACGAAGGCAGCTACTCCT-3\' and 5\'-TTTGGTGGGCTTCTGGTAGG-3\' and the following amplification cycle: 94°C for 4 min; 27 cycles of 94°C for 30 s, 60°C for 30 s and 72°C for 30 s; and 72°C for 5 min. The primers 5\'-TGGGTTATTCCTCCCATCAG-3\' and 5\'-TTTGTCAGGGAGCTCAGGAT-3\' were used to amplify a PCR fragment corresponding to base pairs 590--1066 of human E-cad (accession \# NM_004360.2) and the following amplification cycle: 94°C for 5 min; 25 cycles of 94°C for 60 s, 60°C for 60 s, 72°C for 60 s; and 72°C for 10 min. Using the same amplification protocol, the primers 5\'-TTCGGGTTGTAGGAGTCTTCT-3\' and 5\'-GGTTGCTGATTTTGGTCTTGC-3\' were used to amplify base pairs 3844--4105 of the human c-met mRNA (accession \# NM_000245.2). The housekeeping gene β-actin was used as an internal control and amplified using the primers 5\'-CAAAGACCTGTACGCCAACAC-3\' and 5\'-CATACTCCTGCTTGCTGATCC-3\', corresponding to base pairs 943--1220 of human β-actin (accession \# NM_001101) and the following amplification cycle: 95°C for 3 min; 18 cycles of 95°C for 1 min, 56°C for 1 min and 72°C for 1 min; and 72°C for 10 min.

PCR products were subjected to gel electrophoresis on 1.5% agarose gels. After ethidium bromide staining, DNA bands were photographed under UV illumination using a BioDoc Analyze system (Biometra). Scanned bands were analyzed using the Image J software (NIH, Bethesda, MA, USA) and signal intensities were normalized for actin expression.

Patients and tumour samples
---------------------------

To study expression and interrelation of c-met, Sdc1, and E-cad in preinvasive breast cancer, tissue samples from 200 patients with DCIS were analyzed, with 96 patients exhibiting a pure DCIS and 104 patients showing association of the DCIS with an invasive breast carcinoma. The median age of patients was 59 years (range 18--94 years). Informed consent was obtained from the patients, and the study was carried out in compliance with the Helsinki Declaration. The criteria proposed by Holland and coworkers \[[@B35]\], which consider nuclear grading and architectural differentiation (cellular polarization), were applied to classify all cases, resulting in gradings of low (*n*= 54), intermediate (*n*= 49) and high (*n*= 94). Based on these criteria, cases were finally classified as high-grade DCIS or non-high-grade DCIS (low and intermediate grade). All tissue samples were routinely paraformaldehyde fixed, paraffin embedded and archived at the Gerhard-Domagk Institute of Pathology, Münster University Hospital, Münster, Germany.

To allow permit simultaneous immunohistochemical staining of tissue samples using identical staining conditions, tissue microarrays (TMAs) were constructed from donor tissue blocks as described previously \[[@B36]\]. Following evaluation of haematoxylin and eosin stained microscope slides, at least four morphologically representative regions of each donor block were selected, and a TMA (2 cm × 3.5 cm) containing four to eight core specimens for each DCIS patient was assembled with a manual tissue arrayer (Beecher Instruments, Silver Springs, MD, USA) equipped with a 0.6 mm punch needle. The presence of DCIS in the TMA samples was verified on haematoxylin and eosin stained sections by a pathologist. Lobular carcinoma *in situ*(LCIS), defined by its distinctive histological appearance (characterized by small cells of low nuclear grade that fill and expand lobules without penetration of the basement membrane), was not included in the DCIS TMA. In cases of DCIS with a coexistent invasive carcinoma, only DCIS was included in the TMA sections because the invasive component was not available for analysis.

Immunohistochemistry of TMAs
----------------------------

Consecutive 3 μm sections were cut from the TMA blocks and placed on poly-L-lysine coated coverslips. The dried coverslips were subsequently de-parrafinized, rehydrated and subjected to antigen retrieval by autoclaving in citrate buffer (pH 6.0; DAKO) or microwave treatment, as previously described \[[@B29]\]. After blocking of nonspecific binding, the sections were incubated with the following primary antibodies (specific for human target proteins): mouse anti-syndecan-1 (clone BB4, Serotec; 1:100), rabbit anti-c-met (Santa Cruz; 1:100), mouse anti-E-cadherin (BD Transduction Laboratories; 1:100), rabbit anti-VEGF-A (Santa Cruz; 1:15), rabbit-anti-VEGF-C (Santa Cruz; 1:25), rabbit anti-Flt-1 (Santa Cruz; 1:400), rabbit anti-KDR (Santa Cruz; 1:400), rabbit anti-Flt-4 (Santa Cruz; 1:400), rabbit anti-bFGF (basic FGF; Santa Cruz; 1:2000), rabbit anti-FGFR1 (Santa Cruz; 1:400), mouse-anti-ET-1 (endothelin-1; Affinity Bioreagents, Golden, CO, USA; 1:500), sheep anti-ET~A~R (ETAR; Alexis, Lausen, Switzerland; 1:800), sheep anti-ET~B~R (Alexis; 1:800). Oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER)2 were detected using standard immunohistochemical methods, as described previously \[[@B37]\]. As negative controls, the first antibody was either omitted or isotype-specific control IgGs (monoclonal antibodies) or nonimmune rabbit IgG (polyclonal antibodies) diluted to the same concentration as the first antibody were used. Following washing steps with PBS (three times for 5 min), the primary antibodies were detected using either the DAKO EnVision system (rabbit/mouse) with the Nova Red (Vector Labs) substrate (Sdc1, c-met and E-cad), APAAP (bFGF, Flt-1, KDR and FGFR1) or a labelled streptavidin-horseradish peroxidase method. For more details on retrieval techniques and incubations, the reader is referred to the report by Wülfing and coworkers \[[@B29]\].

Slide scoring and statistical analysis
--------------------------------------

Semiquantitative analysis of staining results of 902 individual tissue array cores was performed by two investigators in a blinded manner without knowledge of the clinical data for the corresponding cases. Only core specimens that were confirmed to contain DCIS were included in the analysis. Consequently, not all cases could be analyzed for each individual marker. Sdc1, c-met and E-cad exhibited predominantly epithelial staining, which for the most part localized to the cell membrane. Additional cytoplasmic staining was frequently observed (for example, see Figure [3](#F3){ref-type="fig"}). Intensity of the immunostaining was scored semiquantitatively on an arbitrary four-tiered scale (negative = 0, weak = 1+, moderate = 2+ and strong = 3+). Grade 0 represented cases with no detectable immunostaining of tumour cells, whereas cases graded as 1+ exhibited weak staining of the majority of tumour cells. Tissue sections with a moderate or strong staining intensity were scored as 2+ or 3+, respectively. In the final score, samples with a moderate or strong immunostaining (score 2+ and 3+) were defined as \'positive\', and samples with a weak or absent immunostaining as \'negative\'.

An analogous scoring system was used to evaluate FGFR1, ET-1, ET~A~R and ET~B~R (cytoplasmic immunostaining), VEGF-C and Flt-4 (cytoplasmic and nuclear immunostaining), and KDR expression (cytoplasmic with occasional membraneous staining) \[[@B36]\]. Similarly, HER2 staining was scored on a scale ranging from 0 (absent) to 3+ (maximum cytomembranous staining), with a score above 2+ considered HER2 positive. The cytoplasmic immunostaining intensity of Flt-1 was classified on a three-tiered scale from 0 (negative) to 2+ (moderate), with cases scored as 1+ and 2+ considered Flt-1 \'positive\'. Expression of bFGF and VEGF-A was characterized as a negative or positive reaction according to both the percentage of stained tumour cells and the immunostaining intensity. When more than 10% of the tumour cells exhibited moderate or strong cytoplasmic immunoreaction, samples were defined as \'positive\' \[[@B31]\]. ER and PR status were defined \'positive\' when more than 10% nuclei stained positively.

Staining results for c-met, Sdc1 and E-cad were correlated with each other and with the expression of angiogenic and lymphangiogenic markers, as well as with ER, PR and HER2 status. In addition, expression of c-met, Sdc1 and E-cad was correlated with the type of DCIS (pure versus coexistent) and nuclear grading. Correlations were tested for statistical significance by cross tables, applying Pearson\'s χ^2^test and Fishers\' exact test using SPSS version 10.0 for Windows (SPSS Inc., Chicago, IL, USA). The Bonferroni adjustment was calculated as α~adj~= 1 - (1 - α)^1/*n*^, with *n*= 17 tests \[[@B38]\].

Results
=======

Colocalization and expression of Sdc1, E-cad and c-met in human breast cancer cell lines
----------------------------------------------------------------------------------------

To characterize the interrelationship between the molecular markers investigated in this study, we performed confocal immunofluorescence microscopy colocalization experiments of c-met with Sdc1 and E-cad in human breast cancer cell lines. MCF-7, MDA-MB468 and MDA-MB231 cells, representing breast cancer cell lines of increasing dedifferentiation and metastatic capacity \[[@B39]\], were stained with antibodies specific for c-met, Sdc1 and E-cad (Figure [1](#F1){ref-type="fig"}). Sdc1 immunoreactivity was primarily located at the cell surface. In MDA-MB468 cells, a fuzzy membranous staining pattern of Sdc1 was observed, possibly indicating alterations in cell-cell contacts. Similar to Sdc1, E-cad staining localized to the plasma membrane. However, an inverse correlation of E-cad expression with the degree of tumour cell de-differentiation was observed, because membraneous staining was almost absent in MDA-MB231 cells. A punctate staining pattern was exhibited by c-met. In MCF-7 cells, c-met partially colocalized with Sdc1 and E-cad. The degree of colocalization appeared to be higher in MCF-7 cells than in MDA-MB468 cells. In MDA-MB231 cells, colocalization with c-met could not be assessed because of the low level of E-cad expression.

We next compared expression of Sdc1, E-cad and c-met at the mRNA level by semiquantitative RT-PCR (Figure [2](#F2){ref-type="fig"}). Similar levels of Sdc1 expression were observed in MCF-7 and MDA-MB468 cells, but Sdc1 mRNA expression was significantly lower (*P*\< 0.001) in MDA-MB231 cells than in MDA-MB468 cells. With increasing de-differentiation and higher metastatic potential (MCF-7 \< MDA-MB468 \< MDA-MB231), a significant decrease in E-cad mRNA expression was observed (Figure [2b](#F2){ref-type="fig"}). Of note, expression levels of c-met exhibited an inverse relation, with the highest expression in MDA-MB231 cells (Figure [2](#F2){ref-type="fig"}).

Immunohistochemical staining of Sdc1, E-cad and c-met in DCIS
-------------------------------------------------------------

We next employed TMA technology to determine the expression of Sdc1, E-cad and c-met in 200 cases of DCIS of the breast. Tumour cells exhibited variable expression of Sdc1, ranging from weak to strong. Staining was predominantly membranous but often additionally cytoplasmic. Stromal cells and myoepithelial cells showed no immunoreactivity (Figure [3](#F3){ref-type="fig"}). For c-met there was weak to strong membrane bound and additional cytoplasmic expression in stromal cells, and myoepithelial cells remained negative (Figure [3](#F3){ref-type="fig"}). Expression of E-cadherin was observed in almost all cases of DCIS, with the majority exhibiting strong immunoreactivity. Staining in tumour cells was membranous and cytoplasmic, whereas stroma and myoepithelium remained negative (Figure [3](#F3){ref-type="fig"}).

Detailed staining results for all three markers in DCIS are listed in Table [2](#T2){ref-type="table"}. Based on a four-tiered scale, moderate to strong positive staining of tumour cells was observed for Sdc1 in 108 out of 150 (72%), for c-met in 69 out of 142 (48.6%) and for E-cad in 101 out of 149 (67.8%) evaluable DCIS samples. We next investigated the interrelation of Sdc1, c-met and E-cad expression. Expression of E-cad was significantly correlated with expression of c-met (*P*= 0.004) and Sdc1 (*P*= 0.007; Table [3](#T3){ref-type="table"}).

Correlation of Sdc1, c-met and E-cad expression with histopathological characteristics
--------------------------------------------------------------------------------------

A significant correlation was observed between expression of c-met and HER2 (*P*= 0.044), and there was a trend toward an association of HER2 with Sdc1 expression (*P*= 0.057; Table [3](#T3){ref-type="table"}). No significant correlation of high-to-moderate c-met, Sdc-1 and E-cad expression with ER and PR status or high-grade DCIS \[[@B35]\] was observed (Table [3](#T3){ref-type="table"}). Expression of c-met (*P*\< 0.001) and Sdc1 (*P*= 0.037) was significantly more frequent in the subgroup of pure DCIS than in the subgroup of DCIS with a coexistent invasive carcinoma (Table [4](#T4){ref-type="table"}). These differences were not due to an unequal distribution of histopathologic or clinical features, because analysis of the distribution of patients\' age, ER, PR and HER2 status, and nuclear grading revealed no statistically significant differences between three subgroups (data not shown).

Correlation of c-met, Sdc1 and E-cad expression with angiogenic and lymphangiogenic factors
-------------------------------------------------------------------------------------------

Expression of four ligand-receptor pairs known to play a role in angiogenesis and lymphangiogenesis was analyzed to test for a potential association of c-met, Sdc1 and E-cad expression with such angiogenic and lymphangiogenic factors: VEGF-A and its receptors Flt-1 and KDR; bFGF and its receptor FGFR1; the endothelin axis, comprised of ET-1 and its receptors ET~A~R and ET~B~R; and the lymphangiogenic factor VEGF-C and its receptor Flt-4 (Table [5](#T5){ref-type="table"}).

VEGF-A exhibited faint to moderate cytoplasmic staining of tumour cells. Positive staining was also observed in myoepithelial cells, whereas normal glandular epithelial cells as well as stromal and connective tissue were mostly VEGF-A negative. KDR staining presented as strong cytoplasmic staining. Normal glandular epithelial cells stained positive for KDR, whereas stroma and connective tissue exhibited no staining. Flt-1 immunoreactivity presented as a granular cytoplasmic staining of tumour cells and of the peritumoural stroma. Normal glandular epithelial cells stained negative for Flt-1.

bFGF staining of tumour cells was predominantly nuclear and occasionally cytoplasmic. Although the stroma was bFGF negative, positive staining of normal glandular epithelial cells was frequently observed. Tumor cells exhibited strong cytoplasmic staining for FGFR1, whereas normal glandular cells were moderately positive, and the majority of stromal cells were weakly positive.

Expression of ET-1, ET~A~R and ET~B~R presented as positive cytoplasmic staining of tumour cells, and a faint additional stromal staining was observed in some ET-1 positive cases. Normal glandular epithelial cells were mostly negative for markers of the endothelin axis.

VEGF-C staining presented as strong cytoplasmic staining of tumour cells, whereas normal breast epithelium was largely VEGF-C negative, as was the stroma and connective tissue. Tumor cells stained strongly positive for Flt-4, and positive staining was also frequently observed in normal glandular epithelium. In contrast, no Flt-4 staining was detected in the stroma and connective tissues.

A highly significant correlation of c-met expression with ET~A~R and ET~B~R was found; 92.6% of c-met positive DCIS versus 56.7% of c-met negative DCIS stained positive for ET~A~R (*P*\< 0.001), and 57.4% of c-met positive tumours versus 23.4% of c-met negative tumours stained positive for ET~B~R (*P*\< 0.001). Furthermore, c-met expression exhibited a significant positive correlation with expression of VEGF-A (*P*= 0.040) and FGFR1 (*P*= 0.028; Table [5](#T5){ref-type="table"}).

Similar to c-met, E-cad expression was significantly correlated with ET~A~R expression (*P*\< 0.001). In addition, we observed a significant correlation of E-cad expression with positive staining for VEGF-A (*P*= 0.005) and VEGF-C (*P*= 0.048).

Sdc1 exhibited a trend toward correlation with lymphangiogenic factors (VEGF-C, *P*= 0.061; Flt-4, *P*= 0.071; Table [5](#T5){ref-type="table"}).

Discussion
==========

In this study we characterized coexpression of the functionally linked prognostic markers Sdc1, E-cad and c-met in 200 DCIS using TMA technology and in different human breast cancer cell lines. Our initial objective was to identify a group of functionally interrelated markers that have prognostic significance in breast cancer. In this regard we observed significant correlations between expression levels for the markers c-met, Sdc1 and E-cad in DCIS. The markers c-met and Sdc1 were significantly more frequently expressed in pure DCIS than in DCIS with a coexistent invasive carcinoma. In the case of Sdc1, this finding may indicate downregulation during epithelial-mesenchymal transition \[[@B40],[@B41]\], which has been demonstrated in mammary epithelial cells *in vitro*\[[@B23],[@B24]\] and during development \[[@B22]\]. Regarding the association between the expression pattern of Sdc1, E-cad and c-met with disease progression, future studies could investigate the correlation with expression for coexisting DCIS and invasive carcinoma. However, based on our cell culture data and on current knowledge on the prognostic value and biological function of the markers (see Table [1](#T1){ref-type="table"}), we speculate that a reduction in E-cad expression and an upregulation of Sdc1 expression may occur in the invasive component of mixed lesions. In the case of c-met, our finding that c-met expression is highest in MDA-MB231 cells, and exhibits a positive correlation with other features of aggressiveness such as HER2 overexpression seemingly contradicts our observation that c-met expression is higher in pure DCIS than in DCIS associated with invasive cancer. We recently observed significantly increased expression of prognostically unfavourable proangiogenic factors in pure DCIS compared with coexistent DCIS \[[@B29]\]. This is consistent with findings reported by Teo and coworkers \[[@B42]\], who described different vascular density and phenotypes in pure versus coexistent DCIS. Therefore, the preferential association of c-met expression with pure DCIS may be indicative of the increased angiogenic activity in pure DCIS \[[@B11],[@B29]\].

The metastatic origin of the investigated human breast cancer cell lines \[[@B39]\] has inherent limitations with respect to a direct comparison of marker expression in DCIS tissue. However, the positive correlation of c-met, Sdc1 and E-cad in an early stage of tumour progression at the tissue level was largely supported by our colocalization studies in these cell lines, in which partial colocalization was observed between c-met and Sdc1 and E-cad, respectively, in the less aggressive MCF-7 and MDA-MB468 cell lines. In addition, Sdc1 and E-cad exhibited a similar cell surface distribution in these cells. Moreover, progressive loss of E-cad expression and a progressive increase in c-met expression were observed with increasing de-differentiation and higher metastatic potential (MCF-7 \< MDA-MB468 \< MDA-MB231) of the breast cancer cell lines at the mRNA level.

These findings are similar to the expression patterns of E-cad and c-met observed in clinical studies. Reduced expression of E-cad in breast carcinoma is associated with shortened disease-free survival and high histological grade \[[@B43]-[@B46]\], whereas high expression of c-met is associated with more aggressive disease and decreased disease-free survival in node-negative breast cancer \[[@B15],[@B47]\] (see Table [1](#T1){ref-type="table"}). In addition, coordinated overexpression of c-met and the oncogene RON is observed in MBA-MB231 but not in MCF-7 cells \[[@B15]\]. Our observation of a synchronous downregulation of E-cad and Sdc1 mRNA in highly aggressive MDA-MB231 cells is in accordance with previous *in vitro*experiments on mammary epithelial cells \[[@B23],[@B24]\]. Expression of Sdc1 can be regulated at the post-transcriptional level \[[@B48],[@B49]\], which may explain the strong Sdc1 protein expression observed by confocal immunofluorescence microscopy in MDA-MB231 cells (Figure [1](#F1){ref-type="fig"}). The heterogeneity in Sdc1 and E-cad coexpression in breast cancer cell lines of different degrees of de-differentiation demonstrates that the concept of synchronous regulation of Sdc1 and E-cad in epithelial cells \[[@B23],[@B24]\] cannot be fully adapted to breast cancer. Our data suggest that the degree of coexpression is higher in breast cells that exhibit a more benign phenotype, such as DCIS, whereas coexpression may be lost in more advanced stages of tumour progression. These findings could help to explain why no correlation was found between E-cad and Sdc1 expression in a patient collective containing ductal invasive, lobular and tubular breast cancer tissues \[[@B8]\], whereas a correlation was found in our more uniform DCIS collective.

We observed no significant association of c-met, E-cad and Sdc-1 expression with hormone receptor status in DCIS. In patient collectives including more advanced stages of breast cancer progression, clinical and experimental data suggest a possible link between loss of E-cad expression and ER-negative status \[[@B20],[@B43],[@B50]\]. Moreover, recent studies have linked Sdc1 expression to an aggressive, ER-negative breast carcinoma subtype \[[@B6]-[@B8]\]. In order to distinguish between low and high expression levels of possibly synchronously regulated Sdc1 and E-cad, both low expression and absence of staining for the markers investigated were scored as \'negative\'. Although application of this scoring method was necessary to detect synchronous coregulation of marker expression, it might have lead to failure to demonstrate significant associations of E-cad expression with hormone receptor status and grade of DCIS in the present study. Although it may occasionally be difficult to distinguish between DCIS and LCIS in cases where LCIS may involve extralobular ducts, we can largely exclude the possibility that the analyzed DCIS cases were erroneously scored as LCIS (see Materials and methods, above).

We found a significant correlation between HER2 and c-met expression. This correlation may be of functional importance, because both molecules are tyrosine kinase receptors that promote cell proliferation \[[@B11],[@B51]\]. Of note, Khoury and coworkers \[[@B51]\] recently demonstrated that HGF-mediated c-met signalling in the presence of constitutively active HER2 leads to a downregulation of E-cad and promotes epithelial-mesenchymal transition in MDCK cells. Thus, signalling downstream of the c-met receptor synergizes with HER2 to enhance a malignant phenotype. In a similar manner, additional receptors could contribute to this synergism in signalling, and our finding of c-met correlating with FGFR1 expression does support this view. Moreover, this hypothesis is supported by a study on the expression of c-met and the tyrosine kinase receptor RON in node-negative breast cancer patients \[[@B15]\]. Ten-year disease-free survival was significantly decreased in patients with tumours expressing only one of the two markers, and it was even worse in patients with RON-positive/c-met-positive tumours. Because Sdc1 is an established coreceptor for several receptor tyrosine kinases, including FGFR1 \[[@B1],[@B3]\] and c-met \[[@B10]\], it could also contribute to synergistic signalling. We observed a trend toward a correlation of Sdc1 and HER2 expression in DCIS (*P*= 0.057). This is in accordance with the study conducted by Barbareschi and coworkers \[[@B6]\], which demonstrated positive correlation of Sdc1 and HER2 in a collective of 254 invasive breast carcinomas. In accordance with its role as a signalling coreceptor, a recent study conducted in 207 breast cancer patients demonstrated a significant association of Sdc1 overexpression with the Ki67 proliferation index \[[@B8]\].

In DCIS, an increase in periductal blood vessels has been correlated with recurrence of invasive disease \[[@B52]\], demonstrating the relevance of angiogenesis to tumour progression. Expression of the angiogenic factor VEGF-A in tumour cells from patients with DCIS was shown to correlate with the degree of angiogenesis \[[@B53]\]. In the present study, we found a significant correlation of both c-met and E-cad with VEGF-A expression in DCIS. In addition, c-met expression exhibited a negative correlation with Flt-1 expression; Flt-1 is a negative regulator of VEGF availability, which is regarded as an antiangiogenic receptor. Our findings constitute the first characterization of a proangiogenic role for c-met, Sdc1 and E-cad in DCIS, but they are in accordance with published work on the biological role of these molecules. Ribozyme targeting of c-met in mammary cancer cells reduced mammary cancer and tumour-associated angiogenesis in a xenograft model \[[@B12]\]. In addition, the HGF-antagonist NK4 inhibits c-met signalling and angiogenesis *in vitro*\[[@B32]\] and reduces intratumoural microvessel density in a hepatocellular carcinoma xenograft model \[[@B54]\]. Sdc1 acts as a coreceptor for several angiogenic and growth factors, including multiple VEGF isoforms and bFGF \[[@B1],[@B3]\]. *In vivo*, we recently demonstrated increased corneal angiogenesis in Sdc-1 deficient mice and the formation of abnormally dilated blood vessels in skin wounds of Sdc-1 overexpressing mice, indicating a regulatory role for Sdc1 in angiogenesis \[[@B2],[@B4]\]. Moreover, in a nude mouse xenograft model, coinjection of MDA-MB-231 breast cancer cells with Sdc-1 overexpressing and mock-transfected mouse fibroblasts resulted in significantly elevated microvessel density and a larger vessel area in tumours containing Sdc1 overexpressing stroma cells \[[@B33]\]. A TMA analysis of 207 human breast cancer samples by the same authors revealed that stromal Sdc1 expression correlated with vessel density and total vessel area, demonstrating a role for Sdc1 in breast tumour angiogenesis.

Although we observed a trend toward an association of Sdc1 expression with markers of lymphangiogenesis, we could not demonstrate a statistically significant correlation of Sdc1 expression and proangiogenic markers in DCIS (Table [5](#T5){ref-type="table"}). This finding may suggest that the angiogenesis-associated functions of Sdc1 primarily contribute to more advanced stages of tumour progression. We have recently demonstrated that VEGF-C and Flt-4, which are established mediators of lymphangiogenesis \[[@B55],[@B56]\], were expressed in the tumour cells of a large proportion (88% to 95%) of DCIS specimens \[[@B29]\]. In the present study, we found a significant association of E-cad with VEGF-C expression (*P*= 0.048). Althuogh very little is known about the role of E-cad in lymphangiogenesis, by virtue of its biological role an involvement in this process could easily be envisaged. Moreover, the correlations of VEGF-A/C with E-cad and of VEGF-A with c-met could be a sign of an angiogenic stimulation of the stroma by the tumour cells \[[@B57]\]. Furthermore, the preferential expression of Sdc1 and c-met in pure versus coexistent DCIS parallels the significantly more common expression of proangiogenic factors in pure versus coexistent DCIS \[[@B29]\].

ET-1 and its G-protein-coupled receptors ET~A~R and ET~B~R (the endothelin axis) are overexpressed in breast carcinomas, and influence angiogenesis, tumourigenesis and tumour progression \[[@B34],[@B36],[@B58]\]. Moreover, we previously demonstrated overexpression of the ET axis in DCIS and observed an association with different angiogenic and lymphangiogenic factors \[[@B29]\]. An important novel finding of the present study is the highly significant association of c-met and E-cad expression with ET receptor expression. Similar to ET~A~R \[[@B34]\], c-met expression is upregulated by hypoxia \[[@B59]\], thus promoting invasive growth of tumour cells. In addition, the c-met ligand HGF has been shown to inhibit ET-1 release in endothelial cells, indicating a possible link between c-met mediated signalling and the ET axis \[[@B60]\]. However, the coexpression of c-met and the ET receptors may simply indicate an upregulation of parallel signalling pathways that utilize different upstream ligands and converge intracellularly. Sdc1 and E-cad have been associated with epithelial-mesenchymal transition \[[@B22],[@B40]\], and it has recently been shown that ET-1 mediated signalling is required during epithelial-mesenchymal transition in ovarian cancer progression \[[@B61],[@B62]\]. In ovarian cancer \[[@B61],[@B62]\] and melanoma \[[@B63],[@B64]\], activation of the ET axis results in downregulated E-cad expression. In DCIS, coexpression of ET receptors, E-cad, c-met and Sdc1 may constitute a specific expression signature indicative of the transition of an early stage to later stages of tumour progression.

One possible caveat associated with the present study is the large number of statistical tests that were performed (*n*= 17). Although the statistical analysis employed in this study permits easier comparison and interpretation of *P*values within the context of the results from other studies, the reader must keep in mind that some significant associations may be falsely positive. Using a Bonferroni adjustment, the corrected significance level for the tests employed in this study would be *P*\< 0.003. However, although corrections for multiple comparisons on the one hand reduce the chances of making a type I error, the chances of making a type II error are increased. Moreover, the relevance of the null hypothesis underlying Bonferroni adjustments has recently been questioned (see the report by Perneger \[[@B38]\] for a discussion). Therefore, there remains a lack of consensus within the scientific community regarding whether corrections for multiple comparisons are applicable.

Conclusion
==========

In the present study we demonstrated coexpression of c-met, Sdc1 and E-cad in DCIS. Of note, expression of c-met, Sdc1 and E-cad correlated with expression of angiogenic and lymphangiogenic factors, including endothelin receptor expression. It is tempting to speculate that this expression signature indicates a state of a parallel, synergistic activation of multiple receptor pathways (receptor tyrosine kinases, G-protein-coupled receptors and nuclear transcription factors), which vastly promote tumour cell proliferation and angiogenesis in the tumour stroma. Since these activation pathways rely on different molecular mechanisms, therapeutic approaches must take multiple targets into consideration. Inhibitors of tyrosine kinases, of the endothelin axis, of heparan sulphate-modulated signalling and of angiogenesis are currently being evaluated in clinical trials or have already found their way into cancer therapies \[[@B5],[@B65]-[@B69]\]. Data from the present study may help in the development of more efficient therapeutic approaches in breast cancer, addressing the need to target simultaneously multiple molecules that are relevant to this early step of breast cancer progression.
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![Immunolocalization of Sdc1, E-cad and c-met in human breast cancer cell lines. The human breast cancer cell lines MCF-7, MDA-MB468 and MDA-MB231 were stained with antibodies specific for c-met (green fluorescent secondary antibody) and Sdc1 or E-cad (red secondary antibodies), and observed by confocal immunofluorescence microscopy. Yellow staining denotes colocalization of c-met with Sdc1 or E-cad. E-cad, E-cadherin; Sdc, syndecan.](bcr1641-1){#F1}

![RT-PCR analysis of Sdc1, E-cad and c-met in human breast cancer cell lines. RNA was prepared from MCF-7, MDA-MB468 and MDA-MB231 breast cancer cells; mRNA was reverse transcribed and used as a template for PCR amplification of Sdc1, E-cad and c-met (as described in Materials and methods section). **(a)**PCR band intensities were normalized for actin expression and the data from three independent experiments were analyzed using the paired Student\'s *t*-test. **(b)**\**P*\< 0.01 (Sdc1: MDA-MB468 versus MDA-MB231; E-cad and c-met: MCF-7 versus MDA-MB231, MCF-7 versus MDA-MB468 and MDA-MB468 versus MDA-MB231). AU, arbitrary units; E-cad, E-cadherin; RT-PCR, reverse transcription polymerase chain reaction; Sdc, syndecan.](bcr1641-2){#F2}

![Representative immunohistochemical staining patterns for E-cad, c-met, and Sdc1 in DCIS. Examples for presence (positive) and absence (negative) of marker expression are shown. DCIS, ductal carcinoma *in situ*; E-cad, E-cadherin; Sdc, syndecan.](bcr1641-3){#F3}

###### 

Cancer-related functions and interrelation of Sdc1, c-met and E-cad

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Marker   Molecular characteristics                                             Biological functions relevant to cancer^a^                                                                              Clinical relevance to breast cancer^a^                                                                                                                  Relation to c-met^a^                                   Relation to E-cad^a^
  -------- --------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------
  Sdc1     Cell surface heparan sulphate proteoglycan                            Cell and matrix receptor \[1\]\                                                                                         Positive correlation with poor prognosis and tumour angiogenesis \[6-8,33\]\                                                                            Sdc1 is c-met co-receptor in multiple myeloma \[10\]   Coordinated regulation and codistribution in mammary tumor cells and epithelial-mesenchymal transition \[22-25\]\
                                                                                 Coreceptor for chemokines, angiogenic and growth factors, and modulator of proteolytic activity \[2-4,16,57\]           Predictive factor in neoadjuvant chemotherapy \[9\]                                                                                                                                                            β-Catenin responsive progenitor cells depend on Sdc1 \[27,28\]

  c-met    Transmembrane tyrosine kinase receptor for hepatocyte growth factor   c-met pathway modulates cell dissociation and motility, protease overexpression and stimulates angiogenesis \[11,12\]   Expression associated with poor outcome in patients with (axillary) lymph node negative breast cancer \[15,47,70\]\                                     Not applicable                                         Correlation with abnormal β-catenin expression suggests downregulation of E-cad/β-catenin by c-met \[73\]
                                                                                                                                                                                                         Negative prognostic factor in breast cancer \[71,72\]                                                                                                                                                          

  E-cad    Epithelial calcium-dependent cell adhesion molecule                   Ensures structural integrity, and contact inhibition of epithelia \[21\]\                                               Membranous staining is independent predictor for disease-free survival in lobular breast cancer \[44\]\                                                 (See Sdc1)                                             Not applicable
                                                                                 Expression changes during epithelial-mesenchymal transition \[40\]\                                                     Loss of expression is associated with negative ER status, high histological grade, metastasis and poor prognosis in breast cancer \[43,45,46,74,75\]\                                                          
                                                                                 Involved in β-catenin-mediated signalling \[20\]                                                                        E-cad is used to distinguish ductal from lobular neopasia \[18,19\]                                                                                                                                            
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Selected examples are given, along with references. E-cad, E-cadherin; ER, oestrogen receptor; Sdc, syndecan.

###### 

Immunohistochemical analysis of Sdc1, c-met and E-cad expression in DCIS of the breast

  Score                   c-met (*n*= 142)   E-cad (*n*= 149)   Sdc1 (*n*= 150)
  ----------------------- ------------------ ------------------ -----------------
  0                       10 (7)             11 (7.4)           4 (2.7)
  1                       63 (44.4)          37 (24.8)          38 (25.3)
  2                       51 (35.9)          89 (59.7)          103 (68.7)
  3                       18 (12.7)          12 (8.1)           5 (3.3)
  Negative (score 0--1)   73(51.4)           48 (32.2)          42 (28)
  Positive (score 2--3)   69 (48.6)          101 (67.8)         108 (72)

Values are expressed as number of evaluable tissue specimens (%). DCIS, ductal carcinoma *in situ*; E-cad, E-cadherin; Sdc, syndecan.

###### 

Interrelation of c-met, E-cad and Sdc1 expression in DCIS and correlation with histopathological characteristics

                    c-met   E-cad    Sdc1                                              
  ----------------- ------- -------- ------- ------- -------- ------- ------- -------- -------
  c-met positive    0.0%    100.0%           30.8%   58.8%    0.004   38.2%   56.3%    0.071
  E-cad positive    56.5%   80.6%    0.004   0.0%    100.0%           51.4%   76.0%    0.007
  Sdc1 positive     66.7%   80.6%    0.071   58.5%   80.9%    0.007   0.0%    100.0%   
  High grade DCIS   47.2%   48.5%    0.877   47.9%   47.5%    0.960   37.5%   49.5%    0.193
  ER positive       25.4%   31.3%    0.463   20.0%   31.5%    0.176   37.1%   26.0%    0.251
  PR positive       33.9%   37.9%    0.643   37.8%   33.7%    0.655   40.0%   31.6%    0.368
  ErbB2 positive    12.5%   27.3%    0.044   23.5%   23.9%    0.964   11.8%   28.0%    0.057

DCIS, ductal carcinoma *in situ*; E-cad, E-cadherin; ER, oestrogen receptor; PR, progesterone receptor; Sdc, syndecan.

###### 

Expression of c-met, Sdc1 and E-cad in the subgroups of pure DCIS and DCIS with coexistent invasive carcinoma

  Molecular marker   Pure DCIS       Coexistent DCIS   *P*
  ------------------ --------------- ----------------- ---------
  Sdc1               59/74 (79.7%)   49/76 (64.5%)     0.037
  c-met              47/72 (65.3%)   22/70 (31.4%)     \<0.001
  E-cad              56/76 (73.7%)   45/73 (61.6%)     0.116

DCIS, ductal carcinoma *in situ*; E-cad, E-cadherin; Sdc, syndecan.

###### 

Correlation of c-met, Sdc1 and E-cad expression with angiogenic and lymphangiogenic factors

           c-met   E-cad   Sdc1                                                
  -------- ------- ------- --------- ------- ------- --------- ------- ------- -------
  VEGF-A   36.2%   53.8%   0.040     26.2%   52.0%   0.005     55%     41.6%   0.149
  Flt-1    18.6%   7.7%    0.063     14.3%   11.5%   0.642     12.8%   12.5%   0.959
  KDR      48.4%   63.1%   0.094     47.4%   56.4%   0.347     45.7%   58.3%   0.198
  VEGF-C   84.5%   94.1%   0.068     80.4%   91.8%   0.048     80.5%   91.5%   0.061
  Flt-4    92.9%   98.6%   0.099     95.1%   97.0%   0.584     90.0%   97.2%   0.071
  ET-1     47.7%   59.7%   0.176     52.4%   48.9%   0.709     47.4%   51.6%   0.661
  ET~A~R   56.7%   92.6%   \<0.001   53.8%   86.9%   \<0.001   70.3%   79.0%   0.277
  ET~B~R   23.4%   57.4%   \<0.001   30.8%   43.3%   0.177     31.6%   47.0%   0.102
  BFGF     17.4%   11.9%   0.394     10.0%   13.4%   0.583     18.9%   11.4%   0.250
  FGFR1    89.1%   98.4%   0.028     92.3%   95.9%   0.394     91.4%   96.0%   0.287

bFGF, basic fibroblast growth factor; E-cad, E-cadherin; ET, endothelin; ET~A/B~R, endothelin A/B receptor; FGFR, fibroblast growth factor receptor; Sdc, syndecan; VEGF, vascular endothelial growth factor.
